2022
Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia
Zhuang J, Zhao Z, Zhang C, Song X, Lu C, Tian X, Jiang H. Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia. Frontiers In Medicine 2022, 9: 1059740. PMID: 36405580, PMCID: PMC9669371, DOI: 10.3389/fmed.2022.1059740.Peer-Reviewed Case Reports and Technical NotesMinimal change diseaseAutoimmune hemolytic anemiaIdiopathic nephrotic syndromeRefractory nephrotic syndromeAdult patientsΒ-thalassemia minorNephrotic syndromeChange diseaseHemolytic anemiaPan B cell marker CD20Treatment of MCDHigh-dose glucocorticoid therapyAdverse effectsClinical complete remissionAdministration of rituximabChimeric monoclonal antibodyLess adverse effectsΒ-thalassemiaAgent regimensComplete remissionGlucocorticoid therapyFrequent relapsesGlucocorticoid dependenceGlucocorticoid resistanceCommon causeEffect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial
Li Y, Fu R, Gao J, Wang L, Duan Z, Tian L, Ge H, Ma X, Zhang Y, Li K, Xu P, Tian X, Chen Z. Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial. Scientific Reports 2022, 12: 255. PMID: 34996948, PMCID: PMC8742122, DOI: 10.1038/s41598-021-03691-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdministration, OralAdultDisease ProgressionDrug TaperingDrug Therapy, CombinationFemaleGlomerulonephritis, IGAGlucocorticoidsHumansKidney Failure, ChronicMaleMethylprednisolonePrednisoneProspective StudiesProteinuriaPulse Therapy, DrugRemission InductionRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsLow-dose prednisoneComplete remissionFP groupIntravenous methylprednisoloneHigh-risk IgA nephropathyOxford MEST-C scoreChinese Clinical Trial RegistryPulsed intravenous methylprednisoloneACEI/ARBClinical Trials RegistryProspective clinical trialsMEST-C scoreFavorable safety profilePercentage of CROral prednisoneTotal remissionAdult patientsNephropathy patientsPrednisone regimenCushing's syndromeMore patientsPrimary outcomeTrials RegistryClinical outcomesIgA nephropathy
2020
Establishment of a novel nomogram for the clinically diagnostic prediction of minimal change disease, −a common cause of nephrotic syndrome
Yan G, Liu G, Tian X, Tian L, Wang H, Ren P, Ma X, Fu R, Chen Z. Establishment of a novel nomogram for the clinically diagnostic prediction of minimal change disease, −a common cause of nephrotic syndrome. BMC Nephrology 2020, 21: 396. PMID: 32928127, PMCID: PMC7490860, DOI: 10.1186/s12882-020-02058-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultArea Under CurveBlood PressureComplement C1qComplement C3Complement C4DiastoleFemaleGlomerular Filtration RateHemoglobinsHumansImmunoglobulin EImmunoglobulin GImmunoglobulin MMaleMiddle AgedNephrosis, LipoidNephrotic SyndromeNomogramsRegression AnalysisReproducibility of ResultsSensitivity and SpecificityYoung AdultConceptsDiastolic blood pressurePrimary glomerular diseaseNephrotic syndromeAdult patientsRenal biopsyChange diseaseGlomerular diseaseBackgroundMinimal change diseaseMinimal change diseaseLASSO regression analysisRenal biopsy procedureNon-MCD groupLogistic regression modelsDiagnostic prediction modelNovel nomogramPatient demographicsBlood pressureSerum levelsOverall incidenceClinical manifestationsMCD patientsMCD diagnosisCommon causeInvasive proceduresMethodA total